WATCH LIVE
timothy sykes logo
SRPT Rises As Sarepta Gains Gene Therapy Momentum Thumbnail
G Google News

SRPT Rises As Sarepta Gains Gene Therapy Momentum

ELLIS HOBBS•UPDATED JUN. 26, 2026, 4:38 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Sarepta Therapeutics Inc. stocks have been trading up by 5.18 percent amid upbeat sentiment on its latest regulatory developments.

What Traders Need To Know

  • RBC reports that Sarepta’s Elevidys franchise for Duchenne muscular dystrophy is stabilizing and that operating expenses are controlled enough to give visibility to near-term cash flow positivity.
  • RBC expects legacy exon-skipping drugs Amondys and Vyondys to sustain roughly $400M in revenue while partnered siRNA programs in facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1 emerge as key future growth drivers, with potential positive data in H2 as a catalyst.
  • The FDA issued draft guidance to streamline development and approval of cell and gene therapies, particularly genome-editing products for serious and rare diseases, by allowing greater use of shared platform data and existing scientific knowledge in submissions.
  • The acting FDA Commissioner told rare-disease nonprofits he is committed to preventing political interference in agency decisions, signaling a focus on scientific standards and regulatory stability for rare-disease and biotech developers.
  • Multiple Form 4 filings disclosed changes in beneficial ownership of Sarepta Therapeutics securities by an insider or major holder, without details on the size, price, or whether the transactions were purchases or sales.

Candlestick Chart

Weekly Update Jun 22 – Jun 26, 2026: On Friday, June 26, 2026 Sarepta Therapeutics Inc. stock [NASDAQ: SRPT] is trending up by 5.18%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Sarepta’s current profile is that of a late‑stage rare‑disease platform transitioning from high-growth, loss-making biotech toward durable profitability. Revenue of ~$2.2B with ~31% 3‑ and 5‑year CAGRs and a 62.9% gross margin underscore strong product economics, but pretax margins remain deeply negative on a normalized basis and ROA/ROE are volatile. Leverage is manageable (total debt/equity 0.69, interest coverage 6.4) with ample liquidity (current ratio 4.6). Free cash flow is still negative but improving as Elevidys scales.

Technically, SRPT is in a short-term corrective phase after failing to hold the 17.50 area, with this week’s range compressing from 17.55 to a 15.81 low before a modest bounce to 16.85. Five‑minute candles show reactive dip‑buying near 16.00–16.20, but no sustained breakout volume above 17.20. The dominant trend on the weekly view is sideways-to-down. Actionable level: 16.00 is key support; a decisive break targets 15.25, while aggressive longs should anchor risk just below 16.00.

Regulatory news is structurally favourable: FDA draft guidance on cell and gene therapies, plus explicit emphasis on science-driven decisions, materially benefits Sarepta’s DMD and broader neuromuscular gene therapy pipeline relative to biotech benchmarks. RBC’s view of Elevidys stabilization and legacy exon-skipping durability supports above‑sector revenue growth versus Healthcare and Biotech indices. Insider Form 4s are noise without size/direction detail. Base case: constructive bias with resistance at 18.50 and support at 16.00; 12‑month risk-adjusted upside target is 22.

More Breaking News

Quick Financial Overview

Sarepta Therapeutics Inc. (SRPT) is trading in a short-term recovery pattern after a pullback. Weekly data show the stock slipping from 17.55 to a low near 15.81, then bouncing back to close around 16.85. Intraday, price built a steady uptrend from about 15.97 at the open toward 17.14 into the close, with shallow intraday pullbacks. That intraday structure signals active dip buying and decent liquidity for short-term trades.

On the fundamentals, Sarepta Therapeutics Inc. generated about $2.20B in revenue over the trailing period, with three- and five-year revenue growth both above 30%. Gross margin near 62.9% shows strong pricing power in its rare disease portfolio. Profit margins are still choppy, with pre-tax margins negative overall, but the latest quarter printed net income of about $331M and EBITDA of $354M, reflecting operating leverage as Elevidys scales.

The balance sheet is serviceable for a commercial-stage biotech. Current ratio of 4.6 and quick ratio of 2.1 point to solid near-term liquidity, while total debt to equity of 0.69 is manageable. Enterprise value near $2.07B against roughly $2.20B of annual revenue translates into a price-to-sales around 1.0, which is low for a gene therapy platform with multiple potential catalysts. RBC’s view that Elevidys stabilization and operating cost control could push SRPT toward near-term cash flow positivity fits with these improving margins.

Conclusion

Sarepta Therapeutics Inc. sits at an important transition point that traders should respect. The tape shows buyers stepping in around the mid-15s and defending into the high-16s and low-17s, which now form a key short-term battleground. As long as SRPT continues to hold above the recent low near 15.80, the path of least resistance is a grind higher on positive headlines and data expectations. In a choppy, catalyst-driven name like this, it’s especially important that traders stick to their process and avoid chasing every intraday move. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.” That mindset applies directly here: respect your levels, respect your plan, and avoid letting headline noise push you into impulsive entries or exits.

On the fundamental side, Elevidys stabilization, durable exon-skipping revenue near $400M, and a growing siRNA pipeline create a clearer multi-franchise story. The latest quarter’s strong revenue and positive net income, combined with a clean liquidity profile and supportive FDA draft guidance for gene therapies, give SRPT a more stable backdrop than many traders may recall from earlier, more speculative phases. Conference appearances in 2026/06 could add headline volatility as management updates on Elevidys trends and second-half readouts.

For active traders, SRPT now trades like a catalyst-driven, medium-beta biotech with real cash flow visibility instead of a pure development lottery ticket. The main risks remain clinical and regulatory execution, plus the usual biotech headline swings. The reward is that any solid H2 data or clearer cash flow path could re-rate a stock currently priced around 1x sales. As I tell my students, “The edge in a name like SRPT comes from marrying the chart with the catalyst calendar — you trade the waves, but you never lose sight of the tide.”

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”